Pharmaceutical

Eloxx Pharmaceuticals Provides ELX-02 and ZKN-013 Program Updates

ELX-02 Granted Orphan Drug Designation (ODD) from U.S. Food and Drug Administration (FDA) for Treatment of Alport Syndrome Pre-Investigational New…

8 months ago

SAB Biotherapeutics Provides SAB-142 Trial Update

MIAMI BEACH, Fla., April 16, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), (“SAB” or the “Company”), a clinical-stage biopharmaceutical…

8 months ago

Clearside Biomedical Appoints Seasoned Biotechnology Executive Anthony S. Gibney to its Board of Directors

- Appointment Adds Broad Expertise in Business Strategy, Collaborations, Finance, and M&A with Recent Ophthalmic Experience - Tony Gibney Tony…

8 months ago

Intra-Cellular Therapies Announces Positive Phase 3 Topline Results from Study 501 Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive Disorder

Lumateperone 42 mg achieved statistically significant and clinically meaningful results in both the primary and the key secondary endpoints Lumateperone…

8 months ago

Vistin Pharma ASA: Invitation to Q1 2024 conference call

Oslo, Norway, 16 April 2024 Vistin Pharma ASA will release its first quarter results on Wednesday 24th of April 2024.…

8 months ago

QuantHealth Appoints Esteemed Pharmaceutical Executives to Inaugural Advisory Board

Leveraging Decades of Experience at AbbVie, Novartis and Biogen, This Advisory Board Will Advocate for AI Integration Within Clinical Trials …

8 months ago

Spago Nanomedical Strengthens Management with Head of CMC & Supply

LUND, SWEDEN / ACCESSWIRE / April 16, 2024 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) Spago Nanomedical AB (publ) today announced the appointment…

8 months ago

Juva Life Unveils New Cannabis Vape Category – Rosin Absolute – Introduces Infused Flower Offerings and Announces Partnership With Cloudius9

REDWOOD CITY, CA / ACCESSWIRE / April 16, 2024 / Juva Life Inc. (CSE:JUVA)(OTCQB:JUVAF)(FRANKFURT:4VV) ("Juva Life" or the "Company"), Juva…

8 months ago

Fresenius Accelerates Momentum in its (Bio)Pharma Business and Launches Tyenne®, its Third Approved Biosimilar in the U.S.

Tyenne® is the first tocilizumab biosimilar by Fresenius Kabi, an operating company of Fresenius SE, with an intravenous and subcutaneous…

8 months ago

Akanda Announces No Equity Financing Until Further Notice

London, United Kingdom--(Newsfile Corp. - April 15, 2024) - Akanda Corp. (NASDAQ: AKAN) ("Akanda" or the "Company"), an international medical…

8 months ago